About Biohaven Ltd
- Industry: Biotechnology
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.biohaven.com/
Frequently Asked Questions
What is the 52-week range for BHVN?
The 52-week high is $18.566 and the 52-week low is $7.48.
What is the P/E ratio for BHVN?
The P/E ratio data is currently unavailable.
What is the dividend yield for BHVN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -639.95%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 28.77.
Analyst Recommendation Trends
Wall Street analyst consensus for BHVN over the last few months:
Latest BHVN News
Roche’s AI lab; Biohaven’s pivotal pause
Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven
Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 202
Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?
Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its...
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation
Warby Parker's 1,500-contract December $22.50 call trade, tied to a stock purchase, signals an institutional covered call. The setup looks bullish on growth and earnings, but a rich valuation, slowing customer growth, and rising capex limit the stock's potential upside.
Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
Biohaven’s epilepsy drug hit with FDA clinical hold
Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Biohaven: The Hold Isn't The Problem (Rating Downgrade)
Biohaven faces challenges following a partial clinical hold on its lead asset, opakalim, and ongoing high cash burn. Read more on BHVN stock here.
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
Biohaven Ltd. (NYSE:BHVN) shares fell 17% on Thursday morning after the company paused new patient enrolment in clinical trials of BHV-7000 following a partial clinical hold from the U.
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?
Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite.
HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regular session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON) shares
These stocks that are showing activity before the opening bell on Thursday.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
FDA places partial hold on Biohaven’s epilepsy drug
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program
Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON) stock
Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
In June 2026, we announced that enrollment in BHV7000-303 was complete. Dosing continues and topline data readout remains on timeline for the second half of 2026. As part of the nonclinical characterization of certain
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says
Biohaven (BHVN) is facing a quieter stretch for major drug catalysts, and limited patient data and r
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target
Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1. 9% to $15.
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19
RBC Capital analyst Leonid Timashev downgrades Biohaven (NYSE:BHVN) from Outperform to Sector Perform and lowers the price target from $23 to $19.
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven’s lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven’s Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Gentile Kimberly | +1,000 | - | - |
| 2026-04-28 | Antonijevic Irina | +68,693 | - | - |
| 2026-04-28 | Mehta Kishan | +68,693 | - | - |
| 2026-04-28 | Heffernan Michael Thomas | +68,693 | - | - |
| 2026-04-28 | Bailey Gregory | +68,693 | - | - |
| 2026-04-28 | HUGIN ROBERT J | +68,693 | - | - |
| 2026-04-28 | GREGORY JULIA P | +68,693 | - | - |
| 2026-04-28 | CHILDS JOHN W | +68,693 | - | - |
| 2026-03-17 | Mehta Kishan | +17,342 | - | - |
| 2026-03-17 | Mehta Kishan | -17,342 | - | - |
| 2026-02-27 | Buten Matthew | +175,000 | - | - |
| 2026-02-27 | Clark George C. | +50,000 | - | - |
| 2026-02-27 | Car Bruce | +175,000 | - | - |
| 2026-02-27 | Coric Vlad | +550,000 | - | - |
| 2026-02-27 | Gentile Kimberly | +175,000 | - | - |
| 2026-01-05 | Buten Matthew | -4,250 | - | - |
| 2026-01-05 | Buten Matthew | -2,594 | $9.93 | $25,758 |
| 2026-01-05 | Buten Matthew | +4,250 | - | - |
| 2026-01-05 | Clark George C. | -2,500 | - | - |
| 2026-01-05 | Clark George C. | -1,117 | $9.93 | $11,092 |
| 2026-01-05 | Clark George C. | +2,500 | - | - |
| 2026-01-05 | Car Bruce | -4,750 | - | - |
| 2026-01-05 | Car Bruce | -2,381 | $9.93 | $23,643 |
| 2026-01-05 | Car Bruce | +4,750 | - | - |
| 2026-01-05 | Coric Vlad | -14,250 | - | - |
| 2026-01-05 | Coric Vlad | -7,430 | $9.93 | $73,780 |
| 2026-01-05 | Coric Vlad | +14,250 | - | - |
| 2026-01-05 | Gentile Kimberly | -3,750 | - | - |
| 2026-01-05 | Gentile Kimberly | -1,956 | $9.93 | $19,423 |
| 2026-01-05 | Gentile Kimberly | +3,750 | - | - |
| 2025-11-17 | Clark George C. | +17,000 | $8.5159 | $144,770 |
| 2025-11-13 | Coric Vlad | +333,333 | $7.5 | $2,499,998 |
| 2025-11-13 | Coric Vlad | +333,333 | $7.5 | $2,499,998 |
| 2025-11-13 | Bailey Gregory | +400,000 | $7.5 | $3,000,000 |
| 2025-11-13 | CHILDS JOHN W | +3,333,333 | $7.5 | $24,999,998 |